Voyager Therapeutics (VYGR) Stock Price, Quote, News & History | Benzinga

SPY778.57+0.60%QQQ751.38+0.51%BTC/USD83,832.96+0.18%DIA516.21+0.89%GLD384.50+1.55%TLT77.97+0.12%

Voyager Therapeutics Inc (VYGR) Stock Price, Quote, News & History

VYGRNASDAQ

Trade with Public

Trade with Public

$2.45

0.083.38%

Last update: Oct 9, 4:52 PM

$2.49

0.125.06%

OverviewNews Earnings Forecast Events Price Targets Financials Sentiment Ownership Compare Options Stock Report

Key Statistics

Open

$2.36

Close

$2.45

Volume / Avg.

690.35K / 577.16K

Day Range

$2.49 - $2.49

52 Wk Range

2.33 - 5.55

Market Cap

$143.20M

P/E Ratio

-

Dividend Yield

-

Exchange

NASDAQ

RSI

32

Short Interest

7.72%

Days to Cover

6.43

Recent Voyager Therapeutics, Inc. News

Jim Cramer: TE Connectivity Is ‘Terrific,’ Buy This Industrial Stock

Jim Cramer recommended buying GE Vernova Inc. as Bernstein analyst initiated coverage with an Outperform rating and $1,206 price target.

Avi Kapoor

J&J Halts Alzheimer's Trial After Drug Fails To Slow Clinical Decline

Johnson & Johnson ends its Phase 2b posdinemab trial after missing key Alzheimer's goals, raising concerns for next-generation tau-targeting drug programs.

Vandana Singh

Voyager Therapeutics Alzheimer's Portfolio And ALPL NeuroShuttle Underscore Platform Momentum: Analyst

Voyager's Alzheimer's programs show longer CNS exposure and potential gene therapy advances, with analysts maintaining a Buy rating and $30 price target.

Vandana Singh

Puma Biotechnology's Q1 Earnings and Revenues Beat

Puma Biotechnology, Inc. (NASDAQ: PBYI) reported first-quarter 2024 adjusted loss of 5 cents per share, which was narrower than the Zacks Consensus Estimate of a loss of 16 cents. In the year-ago quarter, the company had reported adjusted earnings of 9 cents.

Zacks

Analyst Bullish On Gene Therapy-Focused Voyager Therapeutics Sees Best In Class Potential For Its Neurogenetic Medicine Platform

Unlock potential with Voyager Therapeutics as HC Wainwright initiates coverage highlights its TRACER capsid platform, promising CNS-targeted gene therapies and strategic partnerships driving long-term value.

Vandana Singh

Financials

Quarterly

Annual

Name

Revenue Change
Gross Change
EBITDA Change
EBIT Change
Earnings Change

Cash Flows

Operating Cash Flow (TTM)

-120.57M

Investing Cash Flow (TTM)

105.80M

Financing Cash Flow (TTM)

6.46M

Free Cash Flow (TTM)

-121.42M

Capital Expenditure (TTM)

-847.00K

Net Change in Cash (TTM)

-8.31M

Analyst Trends and Forecast

1

Aug

Buy

Hold

Sell

Strong Sell

Analyst Rating and Forecast

4.1

Buy

Strong Buy

Buy

Hold

Sell

Strong Sell

Valuation Metrics

Enterprise Value

$67.19M

PE Ratio (TTM)

-

PE Ratio (FWD)

-

PEG Ratio (TTM)

-

PS Ratio (TTM)

4.23

PB Ratio (TTM)

0.98

Earnings Yield % (TTM)

-73.88%

Earnings Yield % (FWD)

-42.86%

EV / EBITDA (TTM)

-

Price / EBITDA (TTM)

-

Price / Free Cash Flow (TTM)

-

Book Value / Share

$2.51

Company Debt

Total Debt

-

LT Debt

-

LT Debt Issuance (TTM)

-

LT Debt Repayment (TTM)

-

Total Cash

$35.77M

Debt to Equity

0.21

Issuance of Debt (TTM)

-

Repayment of Debt (TTM)

-